

# David E Kloecker Mphil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6659161/publications.pdf>

Version: 2024-02-01

11  
papers

251  
citations

1305906

8  
h-index

1427216

11  
g-index

12  
all docs

12  
docs citations

12  
times ranked

360  
citing authors

#	ARTICLE	IF	CITATIONS
1	Noninferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1598-1606.	2.2	3
2	Association of Timing and Balance of Physical Activity and Rest/Sleep With Risk of COVID-19: A UK Biobank Study. <i>Mayo Clinic Proceedings</i> , 2021, 96, 156-164.	1.4	30
3	Ethnic minorities and COVID-19: examining whether excess risk is mediated through deprivation. <i>European Journal of Public Health</i> , 2021, 31, 630-634.	0.1	20
4	Cardiovascular effects of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The <i>P</i> value and beyond. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1685-1691.	2.2	4
5	Microvascular Disease and Risk of Cardiovascular Events and Death From Intensive Treatment in Type 2 Diabetes. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1458-1469.	1.4	10
6	Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K.. <i>BMC Infectious Diseases</i> , 2021, 21, 908.	1.3	41
7	Association Between Accelerometer-Assessed Physical Activity and Severity of COVID-19 in UK Biobank. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 997-1007.	1.2	18
8	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 172, 541.	2.0	53
9	Number needed to treat in cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists: A systematic review with temporal analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1670-1677.	2.2	9
10	Efficacy and tolerability of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1035-1046.	2.2	46
11	Efficacy of low- and very-low-energy diets in people with type 2 diabetes mellitus: A systematic review and meta-analysis of interventional studies. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1695-1705.	2.2	15